Online citations, reference lists, and bibliographies.
← Back to Search

Breath Analysis: A Systematic Review Of Volatile Organic Compounds (VOCs) In Diagnostic And Therapeutic Management Of Pleural Mesothelioma

A. Catino, G. de Gennaro, A. Di Gilio, L. Facchini, D. Galetta, J. Palmisani, F. Porcelli, N. Varesano
Published 2019 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a rare neoplasm related to asbestos exposure and with high mortality rate. The management of patients with MPM is complex and controversial, particularly with regard to early diagnosis. In the last few years, breath analysis has been greatly implemented with this aim. In this review the strengths of breath analysis and preliminary results in searching breath biomarkers of MPM are highlighted and discussed, respectively. Through a systematic electronic literature search, collecting papers published from 2000 until December 2018, fifteen relevant scientific papers were selected. All papers considered were prospective, comparative, observational case–control studies although every single one pilot and based on a relatively small number of samples. The identification of diagnostic VOCs pattern, through breath sample characterization and the statistical data treatment, allows to obtain a strategic information for clinical diagnostics. To date the collected data provide just preliminary information and, despite the promising results and diagnostic accuracy, conclusions cannot be generalized due to the limited number of individuals included in each cohort study. Furthermore none of studies was externally validated, although validation process is a necessary step towards clinical implementation. Breathomics-based biomarker approach should be further explored to confirm and validate preliminary findings and to evaluate its potential role in monitoring the therapeutic response.
This paper references
10.1111/j.1365-2036.2004.02203.x
Review article: 13C‐urea breath test in the diagnosis of Helicobacter pylori infection – a critical review
J. Gisbert (2004)
10.1016/J.JDENT.2004.06.001
The assessment of methyl mercaptan, an important clinical marker for the diagnosis of oral malodor.
S. Awano (2004)
10.1136/thx.2006.067868
Increased alveolar nitric oxide concentration and high levels of leukotriene B4 and 8-isoprostane in exhaled breath condensate in patients with asbestosis
H. Lehtonen (2007)
A novel method for diagnosing chronic rhinosinusitis based on an electronic nose.
E. Mohamed (2003)
10.1016/J.CHROMA.2005.01.055
Detection of human metabolites using multi-capillary columns coupled to ion mobility spectrometers.
V. Ruzsanyi (2005)
10.1016/S0378-4347(99)00127-9
Variation in volatile organic compounds in the breath of normal humans.
M. Phillips (1999)
10.1177/1403494815596500
Emerging evidence that the ban on asbestos use is reducing the occurrence of pleural mesothelioma in Sweden
B. Järvholm (2015)
10.1088/0967-3334/28/1/007
The suitability of Tedlar bags for breath sampling in medical diagnostic research.
M. M. L. Steeghs (2007)
10.1038/bjc.2017.22
Prognostication and monitoring of mesothelioma using biomarkers: a systematic review
D. Arnold (2017)
Incidence and survival trends for malignant pleural and peritoneal mesothelioma
M J Soeberg (1982)
10.1093/annonc/mdq173
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
R. Stahel (2010)
10.1136/thx.2008.099465
Ion mobility spectrometry for the detection of volatile organic compounds in exhaled breath of patients with lung cancer: results of a pilot study
M. Westhoff (2009)
10.1158/1055-9965.EPI-13-0737
Strengths, Weaknesses, and Opportunities of Diagnostic Breathomics in Pleural Mesothelioma—A Hypothesis
K. Lamote (2014)
10.3109/0284186X.2013.819996
Can dogs smell lung cancer? First study using exhaled breath and urine screening in unselected patients with suspected lung cancer
T. Amundsen (2014)
10.1007/s00408-016-9868-1
Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure
Melike Demir (2016)
Tumours of the Lung, Pleura, Thymus and Hearth
W D Travis (2015)
Analysis of work place compliance measurement of asbestos by the U.S. Occupational Safety and Health Administration
D M Cowan (1984)
10.1002/mas.20303
Progress in SIFT-MS: breath analysis and other applications.
P. Španěl (2011)
10.1016/S1470-2045(18)30765-4
Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel (2019)
10.1007/s00216-012-6102-8
Identification of volatile lung cancer markers by gas chromatography–mass spectrometry: comparison with discrimination by canines
B. Buszewski (2012)
10.18632/oncotarget.13926
RIPK1 prevents aberrant ZBP1-initiated necroptosis
T. Berghe (2017)
Breath analysis for clinical diagnostics and therapeutic monitoring
T. H. Risby (2005)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.1373/clinchem.2015.238840
Ion Mobility in Clinical Analysis: Current Progress and Future Perspectives.
Christopher D Chouinard (2016)
10.1158/1055-9965.EPI-10-0346
Serum Mesothelin for Early Detection of Asbestos-Induced Cancer Malignant Mesothelioma
J. Creaney (2010)
10.1016/S0956-5663(03)00086-1
Lung cancer identification by the analysis of breath by means of an array of non-selective gas sensors.
C. Di Natale (2003)
10.1002/gcc.22670
Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes
M. Betti (2018)
Review article : 13 C - urea breath test in the diagnosis of Helicobacter pylori infection — A critical
J. P. Gisbert (2004)
10.1007/s00216-010-4238-y
Chemical characterization of exhaled breath to differentiate between patients with malignant plueral mesothelioma from subjects with similar professional asbestos exposure
G. Gennaro (2010)
10.1016/B978-0-12-809480-8.00001-7
Chapter 1 – Systematic Review
Susan M. Wilczynski (2017)
10.1016/j.jtho.2017.04.002
Epidemiology of Environmental Exposure and Malignant Mesothelioma.
Bian Liu (2017)
10.1088/1752-7155/3/3/034001
Ion mobility spectrometry coupled with multi-capillary columns for metabolic profiling of human breath.
J. Baumbach (2009)
10.1002/MAS.20033
Selected ion flow tube mass spectrometry (SIFT-MS) for on-line trace gas analysis.
D. Smith (2005)
10.1088/1752-7155/10/4/046001
Detection of malignant pleural mesothelioma in exhaled breath by multicapillary column/ion mobility spectrometry (MCC/IMS).
K. Lamote (2016)
10.1016/j.tibtech.2016.08.005
Artificial Nose Technology: Status and Prospects in Diagnostics.
J. Fitzgerald (2017)
10.1002/PPUL.20056
Childhood asthma: Exhaled markers of airway inflammation, asthma control score, and lung function tests
P. Rosias (2004)
10.1016/j.aogh.2016.01.019
The Global Health Dimensions of Asbestos and Asbestos-Related Diseases.
K. Takahashi (2016)
10.1183/09031936.00051711
Canine scent detection in the diagnosis of lung cancer: revisiting a puzzling phenomenon
R. Ehmann (2011)
10.1002/BMC.835
Human exhaled air analytics: biomarkers of diseases.
B. Buszewski (2007)
10.1183/09031936.00142508
Exhaled biomarkers in lung cancer
I. Horváth (2009)
10.1136/oem.2009.047019
Non-occupational exposure to asbestos and malignant mesothelioma in the Italian National Registry of Mesotheliomas
D. Mirabelli (2010)
10.1155/2014/902748
Oxidative Status and Acute Phase Reactants in Patients with Environmental Asbestos Exposure and Mesothelioma
C. Sezgi (2014)
10.1016/j.lungcan.2011.08.009
An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
S. Dragonieri (2012)
10.1515/CCLM.2009.133
Determination of volatile organic compounds in exhaled breath of patients with lung cancer using solid phase microextraction and gas chromatography mass spectrometry
M. Ligor (2009)
10.1016/j.jchromb.2009.06.008
Rapid and easy method for monitoring oxidative stress markers in body fluids of patients with asbestos or silica-induced lung diseases.
K. Syslová (2009)
10.1021/AC0498260
Demonstration of proton-transfer reaction time-of-flight mass spectrometry for real-time analysis of trace volatile organic compounds.
R. S. Blake (2004)
10.1016/J.CCCN.2004.04.023
Diagnostic potential of breath analysis--focus on volatile organic compounds.
W. Miekisch (2004)
10.1111/j.1440-1843.2006.00852.x
Fractional exhaled nitric oxide concentration is increased in asbestosis and pleural plaques
A. Sandrini (2006)
10.1109/JSEN.2009.2035201
What is Normal Breath? Challenge and Opportunity
Steven F Solga (2010)
10.1093/annonc/mdu357.4
1560PA BREATH TEST FOR DIAGNOSING MALIGNANT PLEURAL MESOTHELIOMA.
Kevin Lamote (2014)
The role of free radicals in asbestos-induced diseases. Free Radic
D W Kamp (1992)
10.1016/S2213-2600(18)30420-X
Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial.
M. Disselhorst (2019)
10.1186/1471-2407-9-348
Noninvasive detection of lung cancer by analysis of exhaled breath
A. Bajtarevic (2009)
10.21037/jtd.2017.10.19
Chemotherapy treatment in malignant pleural mesothelioma: a difficult history.
M. Cinausero (2018)
10.1002/jcp.22724
Malignant mesothelioma: Facts, Myths, and Hypotheses
M. Carbone (2012)
10.1136/thx.54.7.638
The molecular basis of asbestos induced lung injury
D. Kamp (1999)
10.1016/S1470-2045(13)70257-2
Asbestos is not just asbestos: an unrecognised health hazard.
F. Baumann (2013)
10.1002/RCM.1419
Atmospheric pressure matrix-assisted laser desorption/ionization with analysis by ion mobility time-of-flight mass spectrometry.
W. Steiner (2004)
10.1016/j.aca.2018.01.069
Evolution of clinical and environmental health applications of exhaled breath research: Review of methods and instrumentation for gas-phase, condensate, and aerosols.
M. G. Wallace (2018)
10.1016/j.critrevonc.2016.05.004
The Third Italian Consensus Conference for Malignant Pleural Mesothelioma: State of the art and recommendations.
S. Novello (2016)
10.1088/1752-7163/aa7cc0
Comparison of feasibility and estimates of central and peripheral nitric oxide parameters by different mathematical models.
Tuomas Karvonen (2017)
10.1088/1752-7155/8/3/034001
The human volatilome: volatile organic compounds (VOCs) in exhaled breath, skin emanations, urine, feces and saliva.
A. Amann (2014)
10.1155/2012/623019
Role of Nitrative and Oxidative DNA Damage in Inflammation-Related Carcinogenesis
Mariko Murata (2012)
10.1093/bioinformatics/btp093
A new ensemble-based algorithm for identifying breath gas marker candidates in liver disease using ion molecule reaction mass spectrometry
M. Netzer (2009)
10.1158/1078-0432.CCR-15-1130
HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients
A. Napolitano (2016)
10.1093/annhyg/45.8.609
Analysis of solvent vapors in breath and ambient air with a surface acoustic wave sensor array.
W. Groves (2001)
10.1021/AC0501240
Unambiguous identification of volatile organic compounds by proton-transfer reaction mass spectrometry coupled with GC/MS.
Christian Lindinger (2005)
10.1016/S0584-8547(02)00110-6
Ion mobility spectrometer for online monitoring of trace compounds
F. Li (2002)
10.1016/j.lungcan.2013.04.018
A genome-wide association study for malignant mesothelioma risk.
G. Cadby (2013)
10.1016/J.TRAC.2018.07.019
Synergistic approaches for odor active compounds monitoring and identification: State of the art, integration, limits and potentialities of analytical and sensorial techniques
P. Giungato (2018)
10.1016/j.resp.2004.02.002
Mass spectrometric profile of exhaled breath—field study by PTR-MS
B. Moser (2005)
10.5858/arpa.2010-0604-RA
Immunohistochemistry and molecular diagnostics of pleural malignant mesothelioma.
P. Betta (2012)
10.1016/0891-5849(92)90117-Y
The role of free radicals in asbestos-induced diseases.
D. Kamp (1992)
10.3109/13547501003624512
Non-invasive diagnosis of liver diseases by breath analysis using an optimized ion–molecule reaction-mass spectrometry approach: a pilot study
G. Millonig (2010)
10.1164/RCCM.200409-1184OC
Detection of lung cancer by sensor array analyses of exhaled breath.
R. Machado (2005)
10.1073/pnas.1006542107
Programmed necrosis induced by asbestos in human mesothelial cells causes high-mobility group box 1 protein release and resultant inflammation
H. Yang (2010)
Determination of pentane, isoprene and acetone Using HSCC-UV-IMS
Z. Xie (2001)
10.1080/17476348.2019.1563488
Immunotherapy strategies for mesothelioma – the role of tumor specific neoantigens in a new era of precision medicine
L. Ye (2019)
10.1378/CHEST.125.3.1103
Asbestos and the pleura: a review.
D. Cugell (2004)
10.1093/carcin/bgz004
Prognostic factors of survival in patients with malignant pleural mesothelioma: an analysis of the National Cancer Database.
M. V. van Gerwen (2019)
10.18632/oncotarget.21335
Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study
K. Lamote (2017)
10.1183/09059180.00007014
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic
O. D. Røe (2015)
10.1016/j.yrtph.2015.05.002
Analysis of workplace compliance measurements of asbestos by the U.S. Occupational Safety and Health Administration (1984-2011).
Dallas M. Cowan (2015)
10.1186/s12885-018-4452-0
Pancreatic ductal adenocarcinoma can be detected by analysis of volatile organic compounds (VOCs) in alveolar air
A. Princivalle (2018)
10.1016/j.critrevonc.2012.03.001
The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma.
Anthony Linton (2012)
10.1188/15.ONF.552-554
Preferred Reporting Items for Systematic Reviews and Meta-Analyses.
M. Vrabel (2015)
10.1002/ajim.22442
Incidence of malignant mesothelioma of the pleura in Québec and Canada from 1984 to 2007, and projections from 2008 to 2032.
Alfreda Krupoves (2015)
10.1371/journal.pone.0061253
Genetic Variants Associated with Increased Risk of Malignant Pleural Mesothelioma: A Genome-Wide Association Study
G. Matullo (2013)
10.1016/j.rmed.2009.04.009
Exhaled breath condensate biomarkers in asbestos-related lung disorders.
S. Chow (2009)
10.5858/arpa.2015-0240-SA
New Markers for Separating Benign From Malignant Mesothelial Proliferations: Are We There Yet?
A. Churg (2016)
Tumours of the Lung, Pleura, Thymus and Hearth; Iarc
W. D. Travis (2015)
10.1183/13993003.00919-2017
Exhaled breath to screen for malignant pleural mesothelioma: a validation study
K. Lamote (2017)
10.18632/oncotarget.17910
Biomarkers for early diagnosis of malignant mesothelioma: Do we need another moonshot?
Sabrina Lagniau (2017)
10.1183/09031936.00040911
A breath test for malignant mesothelioma using an electronic nose
Elaine. Chapman (2011)
10.1289/EHP.98106573
Trichloroethene levels in human blood and exhaled breath from controlled inhalation exposure.
J. Pleil (1998)
10.21037/tlcr.2017.05.06
Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.
Z. Chen (2017)
10.1371/journal.pone.0046091
Early Detection of Malignant Pleural Mesothelioma in Asbestos-Exposed Individuals with a Noninvasive Proteomics-Based Surveillance Tool
R. Ostroff (2012)
10.1093/NDT/GFG049
Elective haemodialysis increases exhaled isoprene.
P. Lirk (2003)
10.1016/J.TRAC.2006.05.006
From highly sophisticated analytical techniques to life-saving diagnostics: Technical developments in breath analysis
W. Miekisch (2006)
10.1158/0008-5472.CAN-15-0751
Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma.
A. De Rienzo (2016)
10.1016/J.TRAC.2012.11.011
Analytical challenges in breath analysis and its application to exposure monitoring
M. Alonso (2013)
A breath test for diagnosing malignant pleural mesothelioma
K. Lamote (2014)
10.1016/j.jtho.2018.10.163
Peripheral Blood DNA Methylation as Potential Biomarker of Malignant Pleural Mesothelioma in Asbestos‐Exposed Subjects
S. Guarrera (2019)
10.1080/10408340600976499
Current Status of Methods and Techniques for Breath Analysis
Wenqing Cao (2007)
10.1088/1752-7155/4/1/017104
LC-ESI-MS/MS method for oxidative stress multimarker screening in the exhaled breath condensate of asbestosis/silicosis patients.
K. Syslová (2010)
10.1007/s11864-019-0613-x
Use of Immune Checkpoint Inhibitors in Mesothelioma
P. Forde (2019)
10.1007/s12127-014-0147-7
Signals in asbestos related diseases in human breath - preliminary results
Y. Çakir (2014)
10.1088/1752-7155/8/1/014001
A review of the volatiles from the healthy human body.
B. D. L. de Lacy Costello (2014)
10.1016/0378-4347(94)00545-G
Measurement of volatile organic compounds in exhaled breath as collected in evacuated electropolished canisters.
J. Pleil (1995)
10.2486/INDHEALTH.46.484
Increased 8-isoprostane, a marker of oxidative stress in exhaled breath condensate in subjects with asbestos exposure.
D. Pelclova (2008)
10.1136/oemed-2015-103309
Incidence and survival trends for malignant pleural and peritoneal mesothelioma, Australia, 1982–2009
M. Soeberg (2016)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar